Skip to Content

Urology

ADSTILADRIN Early Utilization and Outcomes in the Real-World Setting in the United States Study

The ADSTILADRIN Early Utilization and Outcomes in the Real-World Setting in the United States study examines how ADSTILADRIN (intravesical Instiladrin therapy) is being used in routine clinical practice and its effects on patients with non-muscle invasive bladder cancer (NMIBC). The study collects real-world data on treatment patterns, safety, tolerability, and clinical outcomes to better understand the therapy’s effectiveness outside of controlled clinical trials. Insights from this research aim to inform clinicians, guide patient management, and support optimal use of ADSTILADRIN in everyday urologic care. This study’s principal investigator is Leonardo Borregales, MD.

Evaluating the Impact of Day of the Week on Urological Surgery Outcomes Study

The Evaluating the Impact of Day of the Week on Urological Surgery Outcomes study investigates whether the day a patient undergoes urological surgery affects post-operative results. By analyzing surgical outcomes, complications, recovery times, and other relevant clinical data across different weekdays, the study aims to determine if timing plays a role in patient safety and treatment effectiveness. The findings could help optimize surgical scheduling, improve patient outcomes, and guide healthcare resource planning in urology. This study’s principal investigator is Alon Z. Weizer, Doyle and Rodriguez Family Chief Medical Officer.

Expanded Access Use of Recombinant Bacillus Calmette-Guérin (rBCG) in Nonmuscle Invasive Bladder Cancer Study

The Expanded Access Use of Recombinant Bacillus Calmette-Guérin (rBCG) in Nonmuscle Invasive Bladder Cancer study provides eligible patients with access to an investigational recombinant BCG therapy for the treatment of nonmuscle invasive bladder cancer (NMIBC). This study aims to evaluate the safety, tolerability, and preliminary effectiveness of rBCG in patients who may not have other suitable treatment options. Participants receive the therapy under careful clinical monitoring, allowing researchers to collect data on immune response, side effects, and treatment outcomes. By expanding access to rBCG, the study seeks to offer a promising therapeutic option while gathering evidence to support future clinical use in NMIBC management. This study’s principal investigator is Akshay Bhandari, MD, Shelia & Charles D. Saunders, M.D, F.A.C.S. Co-Chief, Urology, Director, Robotic Surgery..

NIMBIC Cohort

The NIMBIC Cohort is a clinical research study for patients with non-muscle invasive bladder cancer (NMIBC). It aims to better understand disease biology, treatment response, and recurrence risk by collecting clinical data, tissue samples, and follow-up information. The study’s goal is to identify biomarkers and improve personalized treatment strategies to enhance patient outcomes. This study’s principal investigator is Alan M. Nieder, MD, Shelia & Charles D. Saunders, M.D, F.A.C.S. Co-Chief, Division of Urology, Program Director, Urology Residency Program.

uTRACT Jelmyto® Registry Study

The uTRACT Jelmyto® Registry is a real-world observational study designed to collect data on the use of Jelmyto® (mitomycin-containing hydrogel) in patients with low-grade upper tract urothelial carcinoma (UTUC). The registry tracks treatment patterns, safety, effectiveness, and patient outcomes in routine clinical practice. By capturing real-world experience, the study aims to provide insights into how Jelmyto® performs outside of clinical trials, helping inform clinical decision-making and optimize patient care. This study’s principal investigator is Alan M. Nieder, MD, Shelia & Charles D. Saunders, M.D, F.A.C.S. Co-Chief, Division of Urology, Program Director, Urology Residency Program
Back to top